Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,952.80
(
0.88%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
96.50
(
-4.62%
)
Bitcoin
76,651.59
(
-0.80%
)
News Focus
News Focus
Post# of 881
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 99

Tuesday, 09/13/2011 3:23:06 PM

Tuesday, September 13, 2011 3:23:06 PM

Post# of 881
ABT ‘ReadMeFirst’ updated:

Elagolix starts phase-2 in uterine fibroids;
economic terms of Elagolix partnership with NBIX;
FDA approves companion diagnostic for PFE’s Xalkori;
testing of Absorb begins in critical limb ischemia;
new musings on competitive threat to Humira from PFE’s Tofacitinib.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67058123

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ABT News
More ABT News